Rho激酶抑制剂对不稳定型心绞痛患者疗效的观察  

Effects of Rho-kinase inhibitors in patients with unstable angina pectoris

作　　者：杨斌[1] 郑春燕[1] 宇仁超[1] 李珊[1] 谭丽娟[1] 

机构地区：[1]青岛大学附属医院心血管内科,山东青岛266003

出　　处：《岭南心血管病杂志》2014年第5期578-580,共3页South China Journal of Cardiovascular Diseases

摘　　要：目的观察Rho激酶抑制剂(法舒地尔)对不稳定型心绞痛患者的疗效及其对血浆高敏C-反应蛋白(high-sensitivity C-reactive protein,hs-CRP)、白细胞介素-1(interleukin-1,IL-1)浓度的影响。方法将58例经冠状动脉造影证实的不稳定型心绞痛患者分为常规治疗组和法舒地尔治疗组。常规治疗组(n=28)给予常规药物治疗(阿司匹林、低分子肝素、β-受体阻断药、他汀类药物、硝酸酯类和钙离子拮抗剂等);法舒地尔治疗组(n=30)在常规治疗基础上加用法舒地尔60 mg,加入0.9%氯化钠溶液250 mL每天1次,静脉注射14 d。观察并比较两组治疗后总有效率及其血浆中hs-CRP和IL-1浓度。结果法舒地尔治疗组治疗14 d后总有效率明显高于常规治疗组,差异有统计学意义(P<0.05)。两组治疗后血浆hs-CRP和IL-1浓度较治疗前降低,差异有统计学意义(P<0.05);但法舒地尔组改变较常规治疗组更为明显,差异有统计学意义(P<0.05)。结论法舒地尔可能通过阻止组织因子的表达和凝血酶的形成,抑制粥样硬化病变的炎性反应,从而稳定斑块,减少急性心脏缺血事件的发生。Objectives To observe the effects of Rho-kinase inhibitors on high-sensitivity C-reactive protein （hs-CRP）and interleukin-1 （IL-1） in patients with unstable angina pectoris （UAP）.Methods A total of 58 patients with UAP confirmed by coronary angiography were recruited and divided into two groups：conventional therapy group （n=28） and Rho-kinase inhibitor （fasudil） therapy group （n=30）.Basic medication including aspirin,low-molecular-weight heparins,beta receptor blockers,statins,nitrates and calcium antagonists were used in the two groups,fasudil （60 mg in 250 mL 0.9% NaCl,intravenous infusion,once a day,14 days as 1 course） was added in fasudil therapy group.Total effectiveness rate was observed and concentrations of hs-CRP and IL-1 were measured by enzyme-linked immunosorbent assay （ELISA） at baseline and 14 days later in the two groups.Results Total effectiveness rate was obviously higher in fasudil therapy group than in conventional therapy group after treatment for 14 days （P〈0.05）.Concentrations of hs-CRP and IL-1 in the two groups after treatment significantly decreased than those at baseline （P〈0.05）,and they were obviously lower in fasudil therapy group compared with conventional therapy group （P〈0.05）.Conclusions Rho-kinase inhibitors （fasudil） can inhibit the inflammatory response in patients with atherosclerotic heart disease by preventing tissue factor expression and thrombin formation,which may contribute to the stability of atherosclerotic plaques and improvement of myocardial ischemia.

关 键 词：心绞痛 不稳定型 高敏C-反应蛋白 白细胞介素-1 RHO激酶抑制剂 

分 类 号：R541.4[医药卫生—心血管疾病]